Answers are grounded in this paper and cite their sources.
Direct oral anticoagulants (DOACs) are highlighted as an important option for VTE management in recent guidelines.
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism, is a common cardiovascular disease associated with significant morbidity ranging from painful leg swelling, chest pain, shortness of breath, and even death. Long-term complications include recurrent VTE, postpulmonary embolism syndrome, chronic thromboembolic pulmonary hypertension, and postthrombotic syndrome (PTS). Management of VTE requires immediate anticoagulation therapy based on a risk assessment for bleeding. Direct oral anticoagulants (DOACs) have become an important option for patients as reflected in the most recent American College of Chest Physician treatment guidelines.
No takes yet. Share an insight, caveat, or question.
John R. Bartholomew (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: